The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM).

Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma

Zucali PA;Santoro A
2013-01-01

Abstract

The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM).
2013
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Disease-Free Survival
Female
Glutamates
Guanine
Humans
Kaplan-Meier Estimate
Male
Mesothelioma
Middle Aged
Pemetrexed
Pleural Neoplasms
Treatment Outcome
Vascular Endothelial Growth Factor A
File in questo prodotto:
File Dimensione Formato  
pdf.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 303.5 kB
Formato Adobe PDF
303.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/12448
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 66
social impact